Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 10 W ELECTROLYTES versus AMINOSYN II 7 W ELECTROLYTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 10 W ELECTROLYTES versus AMINOSYN II 7 W ELECTROLYTES.
AMINOSYN II 10% W/ ELECTROLYTES vs AMINOSYN II 7% W/ ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amino acids serve as substrates for protein synthesis and nitrogen balance; electrolytes maintain osmotic and acid-base balance.
Provides essential and non-essential amino acids for protein synthesis, promotes nitrogen balance, and serves as a caloric source in parenteral nutrition.
1-2 g/kg/day (0.1-0.2 g/kg/hour) IV via central line as continuous infusion.
Adults: 500 mL to 2000 mL/day intravenously via central line at a rate not exceeding 100 mL/hour. Dosage based on protein requirement (0.8-1.5 g/kg/day) and nutritional status.
None Documented
None Documented
The terminal elimination half-life of individual amino acids varies but is generally short (range 0.5–2 hours) due to rapid uptake and metabolism. Clinically, the half-life of infused amino acids is not a relevant parameter for dosing; rather, infusion rate is adjusted to maintain nitrogen balance.
Variable; amino acids: 10–40 minutes (rapid distribution and metabolism); clinical context: continuous infusion required to maintain steady state
Amino acids are primarily metabolized to urea and other nitrogenous waste products, which are excreted renally (90-95% of total nitrogen excreted as urea). Unmetabolized amino acids in plasma are also filtered and reabsorbed by the kidneys; negligible amounts are excreted unchanged (<5%). Biliary/fecal excretion is minimal (<2%).
Renal: >80% as amino acids and metabolites; fecal: negligible; biliary: <5%
Category C
Category C
Amino Acid Solution
Amino Acid Solution